Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-05-12 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于双润正安信息咨询（北京）有限公司要约收购江苏浩欧博生物医药股份有限公司之2025年第一季度持续督导意见
M&A Activity Classification · 95% confidence The document is titled as a "2025 First Quarter Continuous Supervision Opinion" issued by China International Capital Corporation Limited regarding a tender offer acquisition of Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It details the ongoing supervision and compliance with laws and regulations during the tender offer period, including transaction progress, governance, commitments, and plans related to the acquisition. The document contains detailed information about the acquisition process, governance, management changes, and compliance, but it is not a full annual or quarterly financial report. It is a specialized report related to the ongoing monitoring of a tender offer acquisition, which aligns with the category of M&A Activity (TAR) filings that cover announcements and documents related to merger proposals or takeover bids. The document length (6585 characters) and content indicate it is a substantive report, not merely an announcement or certification. Therefore, the best classification is TAR (M&A Activity).
2025-05-12 Chinese
江苏浩欧博生物医药股份有限公司2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions from the 2025 first extraordinary general meeting of shareholders of Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes information about the meeting date, attendance, voting results on director elections, and legal witness statements. The content focuses on the voting outcomes and procedural compliance of the shareholder meeting. There is no financial data, no report attached or referenced as published, and no indication of an annual or interim report. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1881 characters), but it contains detailed voting results, not just a notice of report publication. Therefore, the correct classification is DVA with high confidence.
2025-05-07 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2025年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and legality of the 2025 first extraordinary general meeting (临时股东大会) of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the legality of the meeting's call, attendance, voting procedures, and results. It is not a report of financial results, audit, or management discussion, but a legal opinion on the shareholder meeting process. This type of document is best classified under Declaration of Voting Results & Voting Rights Announcements (DVA) because it relates to the official validation and legal opinion on the shareholder meeting and voting process. The document length is short and focused on legal opinion rather than the full meeting materials or minutes, so it is not AGM Information (AGM-R).
2025-05-07 Chinese
江苏浩欧博生物医药股份有限公司关于调整第三届董事会专门委员会成员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding changes in the composition of the company's board committees following a shareholders' meeting and a board meeting. It details the adjustment of members in various board committees such as the Strategy Committee, Audit Committee, Nomination Committee, and Remuneration and Assessment Committee. There is no financial data, no mention of annual or quarterly reports, no earnings information, and no regulatory filings or certifications. The content clearly relates to changes in the company's board or senior management structure. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused solely on board committee member changes, confirming this classification with high confidence.
2025-05-07 Chinese
江苏浩欧博生物医药股份有限公司2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏浩欧博生物医药股份有限公司2025 年第一季度报告" which translates to "Jiangsu Haobo Biomedical Co., Ltd. 2025 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management assurances about the accuracy of the quarterly report. The report explicitly states it is for the first quarter of 2025, indicating it is an interim or quarterly financial report. The document length is over 12,000 characters and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
江苏浩欧博生物医药股份有限公司2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2025 年第一次临时股东大会会议资料' which translates to '2025 First Extraordinary General Meeting (EGM) Meeting Materials'. It contains detailed information about the meeting agenda, voting procedures, and proposals for the election of non-independent directors to the board. The content is focused on the meeting materials for a shareholder meeting, including instructions, agenda, and proposals to be voted on. It is not a report of financial results, audit, or earnings, nor is it a simple announcement or voting result. It is clearly the presentation and materials shared during a shareholder meeting, which fits the definition of AGM Information (AGM-R), even though this is an extraordinary meeting rather than an annual one, the category AGM-R covers presentations and materials shared during general meetings. The document length is 4145 characters, which is consistent with a meeting material document rather than a brief announcement or a full report. Therefore, the correct classification is AGM Information (AGM-R).
2025-04-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.